Composition for diagnosing mild cognitive impairment and kit thereof

A diagnostic composition and kit detect specific microbial strains in fecal samples to accurately diagnose mild cognitive impairment, addressing the need for early detection and differentiation from dementia.

WO2026240435A1PCT designated stage Publication Date: 2026-11-19AJOU UNIV IND ACADEMIC COOP FOUND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/006049
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2026-05-13
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current methods lack an effective means to diagnose mild cognitive impairment at its earliest stage, which is crucial for maximizing treatment effectiveness.

Method used

A diagnostic composition and kit that utilize a preparation capable of detecting specific microbial strains, including Blautia, Streptococcus, Bacteroides, Eubacterium hallii, Dorea, Clostridia UGG-014, and Weisella, from fecal samples using primers, probes, or antibodies to identify these strains based on 16S rRNA sequences.

Benefits of technology

Enables accurate diagnosis of mild cognitive impairment by monitoring the weight ratios of these microbial strains, distinguishing it from dementia, thereby facilitating early detection and appropriate treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026006049_19112026_PF_FP_ABST
    Figure KR2026006049_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to a composition for diagnosing mild cognitive impairment, the composition comprising an agent capable of detecting a strain of Blautia, a strain of Streptococcus, a strain of Bacteroides, a strain of Eubacterium hallii, a strain of Dorea, a strain of Clostridia UCG-014, and a strain of Weissella from a fecal sample of a subject.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for diagnosing mild cognitive impairment and kit thereof

[0001] The present invention relates to a composition for diagnosing mild cognitive impairment and a kit thereof, and more specifically, to a composition for diagnosing mild cognitive impairment comprising a preparation capable of detecting a mixture of microorganisms.

[0002] Mild cognitive impairment refers to a condition in which cognitive function, particularly memory, is lower than that of the same age group, but the ability to perform daily activities is preserved, meaning it is not yet dementia. In other words, mild cognitive impairment can be considered an intermediate stage between normal aging and dementia.

[0003] Mild cognitive impairment is the stage where Alzheimer's disease can be detected at the earliest stage, and it is important because early detection can maximize the effectiveness of treatment.

[0004] The present invention was derived from research conducted as part of the Ministry of Health and Welfare's Research-Oriented Hospital Development (Project Unique Number: 2460000110, Project Number: RS-2022-KH130303, Project Management Agency: Korea Health Industry Development Institute, Research Project Name: Super-Gap SUPER*Senior Total Health Care Platform, Project Performing Agency: Ajou University Medical Center, Research Period: 2025.01.01 ~ 2025.12.31).

[0005] In addition, the present invention was derived from research conducted as part of the Ministry of Health and Welfare's Research-Oriented Hospital Development (Project Unique Number: 2460000763, Project Number: RS-2021-KH113821, Project Management Agency: Korea Health Industry Development Institute, Research Project Name: Establishment of Human-Environmental Interaction Beyond Target Platform, Project Executing Agency: Ajou University Industry-Academic Cooperation Foundation, Research Period: 2025.01.01 ~ 2025.12.31).

[0006] In addition, the present invention is derived from research conducted as part of the Multi-Ministerial Research and Development Project for Overcoming Dementia (Ministry of Health and Welfare, Ministry of Science and ICT) (Project Unique Number: 2460000573, Project Number: RS-2024-00339665, Project Management Agency: Korea Health Industry Development Institute, Research Project Name: Development of Technology for Enhancing Brain Cognitive Reserve Based on Big Data AI Model, Project Executing Agency: Korea Advanced Institute of Science and Technology, Research Period: 2025.01.01 ~ 2025.12.31).

[0007] In addition, the present invention was derived from research conducted as part of the Ministry of Science and ICT’s group research support (R&D) (Project No.: 2710036689, Project No.: RS-2019-NR040055, Project Management Agency: National Research Foundation of Korea, Research Project Name: Brain Disease Convergence Research Center, Project Performing Agency: Ajou University, Research Period: 2025.03.01 ~ 2026.02.28).

[0008] In addition, the present invention was derived from research conducted as part of the Korea Disease Control and Prevention Agency's Comprehensive Management of Health and Medical Biological Resources (Project Unique Number: 2770000043, Project Number: 2024-ER0505-00, Project Management Agency: Korea Health Industry Development Institute, Research Project Name: Innovative Biobank Consortium for Research on Chronic Cerebrovascular Disease (1st Year), Project Performing Agency: Ajou University Industry-Academic Cooperation Foundation, Research Period: 2025.01.31 ~ 2025.12.31).

[0009] Meanwhile, the Korean government, the provider of the problem, has no property interest in all aspects of the present invention.

[0010] The various embodiments described herein are intended to provide a diagnostic composition and a kit thereof comprising a preparation capable of detecting a microbial mixture for diagnosing mild cognitive impairment.

[0011] The problems that this disclosure aims to solve are not limited to those described above, and other unmentioned problems will be clearly understood by a person skilled in the art from the description below.

[0012] A composition for diagnosing mild cognitive impairment according to one embodiment may include a preparation capable of detecting Blautia genus strains, Streptococcus genus strains, Bacteroides genus strains, Eubacterium hallii genus strains, Dorea genus strains, Clostridia UGG-014 genus strains, and Weisella genus strains from a fecal sample of a subject.

[0013] Here, the Streptococcus genus strain is Streptococcus salvarius, and the Weisella genus strain may be Weisella confusa.

[0014] Here, the formulation may additionally include one or more strains selected from the group consisting of strains of the genera Collinsella, Romboutsia, and Anaerostipes.

[0015] Here, the above-mentioned strain of the genus Collinsella may be Collinsella aerofaciens.

[0016] Here, the agent capable of detecting the strain may be a primer, probe, antisense oligonucleotide, aptamer, or antibody specific to the microorganism.

[0017] Here, the primer may be a primer capable of amplifying the 16S rRNA of the strain.

[0018] A kit for diagnosing mild cognitive impairment comprising the above diagnostic composition according to another embodiment may be provided.

[0019]

[0020] A method for providing information necessary for diagnosing mild cognitive impairment according to another embodiment may include the step of detecting Blaufia strains, Streptococcus strains, Bacteroides strains, Eubacterium hallii strains, Dorea strains, Clostridia UGG-014 strains, and Weisella strains from a fecal sample of a subject.

[0021] Here, if the Blautia strain is included in the total sample at a weight of 0.01 to 0.1%, the step of determining the subject has mild cognitive impairment may be included.

[0022] Here, if the Streptococcus strain is included in the total sample at a weight of 0.05 to 0.1%, the step of determining the subject has mild cognitive impairment may be included.

[0023] Here, if the Clostridia UGG-014 strain is included in the total sample at a weight of 0.01 to 0.1%, the method may include a step of determining the subject as having mild cognitive impairment.

[0024] Here, if the above Weisella strain is included in the total sample at a weight of 0.01 to 0.1%, the step of determining the subject has mild cognitive impairment may be included.

[0025] According to one embodiment of the present invention, a composition for diagnosing mild cognitive impairment may be provided, comprising a preparation capable of detecting a mixture of microorganisms to effectively diagnose mild cognitive impairment.

[0026] The effects according to the present invention are not limited to those described above, and other unmentioned effects will be clearly understood by a person skilled in the art from the description below.

[0027] Figure 1 is a figure confirming the beta diversity of microbial genera between the SMI+MCI group and the Dementia group according to one embodiment.

[0028] Figure 2 is a figure confirming the beta diversity by microbial species between the SMI+MCI group and the Dementia group according to one embodiment.

[0029] Figure 3 is a bar graph showing the composition ratio of intestinal microorganisms in the SMI+MCI group and the Dementia group according to one embodiment.

[0030] Figure 4 is a graph showing the weight percentage of intestinal microorganisms in the SMI+MCI group and the Dementia group according to one embodiment.

[0031] Figure 5 is a bar graph showing the composition ratio of intestinal microbial species in the SMI+MCI group and the Dementia group according to one embodiment.

[0032] Figure 6 is a graph showing the weight percentage of intestinal microbial species in the SMI+MCI group and the Dementia group according to one embodiment.

[0033] Figure 7 is a bar graph showing the composition ratio of the intestinal microbial genera of the SMI group, MCI group, and Dementia group according to one embodiment.

[0034] FIG. 8 is a graph showing the weight percentage of intestinal microorganisms in the SMI group, MCI group, and Dementia group according to one embodiment.

[0035] FIG. 9 is a bar graph showing the composition ratio of intestinal microbial species in the SMI group, MCI group, and Dementia group according to one embodiment.

[0036] FIG. 10 is a graph showing the weight percentage of intestinal microbial species in the SMI group, MCI group, and Dementia group according to one embodiment.

[0037] One aspect may provide a composition for diagnosing mild cognitive impairment comprising a preparation capable of detecting Blautia genus strains, Streptococcus genus strains, Bacteroides genus strains, Eubacterium hallii genus strains, Dorea genus strains, Clostridia UGG-014 genus strains, and Weisella genus strains from a fecal sample of a subject.

[0038] In this document, the term “microbiome” refers to the entire genetic information of microorganisms coexisting within the human body, and in this invention, the microbiome refers to the entire genetic information of microorganisms present in feces.

[0039] In this invention, the term "Blautia" refers to a microorganism or a community thereof composed of species taxonomically belonging to the genus Blautia. In this invention, Blautia includes not only previously known strains but also strains having sequence homology of at least 70%, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95% when comparing 16S rRNA sequences with previously known Blautia.

[0040] In this invention, the term "Streptococcus" refers to a microorganism or a community thereof composed of species taxonomically belonging to the genus Streptococcus. In this invention, Streptococcus includes not only previously known strains but also strains having sequence homology of preferably 70% or more, more preferably 80% or more, even more preferably 90% or more, and most preferably 95% or more when comparing 16S rRNA sequences with previously known Streptococcus.

[0041] In one embodiment, the Streptococcus genus strain may be Streptococcus salvarius.

[0042] In this invention, the term "Bacteroides" refers to a microorganism or a community thereof composed of species taxonomically belonging to the genus Bacteroides. In this invention, Bacteroides includes not only previously known strains but also strains having sequence homology of preferably 70% or more, more preferably 80% or more, even more preferably 90% or more, and most preferably 95% or more when comparing 16S rRNA sequences with previously known Bacteroides.

[0043] In this invention, the term "Eubacterium hallii" refers to a microorganism or a community thereof composed of species taxonomically belonging to the genus Eubacterium hallii. In this invention, Eubacterium hallii includes not only previously known strains but also strains having sequence homology of preferably 70% or more, more preferably 80% or more, even more preferably 90% or more, and most preferably 95% or more when comparing 16S rRNA sequences with previously known Eubacterium hallii.

[0044] In this invention, the term "Dorea" refers to a microorganism or a community thereof composed of species taxonomically belonging to the genus Dorea. In this invention, Dorea includes not only previously known strains but also strains having sequence homology of at least 70%, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95% when comparing 16S rRNA sequences with previously known Dorea.

[0045] In this invention, the term "Clostridia UGG-014" refers to a microorganism or a community thereof composed of species taxonomically belonging to the genus Clostridia UGG-014. In this invention, Clostridia UGG-014 includes not only previously known strains but also strains having sequence homology of at least 70%, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95% when comparing 16S rRNA sequences with previously known Clostridia UGG-014.

[0046] In this invention, the term "Weisella" refers to a microorganism or a community thereof composed of species taxonomically belonging to the genus Weisella. In this invention, Weisella includes not only previously known strains but also strains having sequence homology of at least 70%, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95% when comparing 16S rRNA sequences with previously known Weisella.

[0047] In one embodiment, the Weisella genus strain may be Weisella confusa.

[0048] In this institution, the term "dementia" refers to a severe impairment of cognitive function that interferes with daily life or social life, specifically distinct from Alzheimer's disease, and may mean a case where the Clinical Dementia Rating (CDR) is 1 or higher.

[0049] At our institution, the term "mild cognitive impairment (MCI)" refers to a condition in which cognitive function, particularly memory, is lower than that of the same age group, but the ability to perform daily activities is preserved, so it may not yet be dementia.

[0050] In this institution, the term "subjective memory impairment (SMI)" may refer to a condition in which a patient subjectively complains of impaired memory despite performance in objective memory tests being within the normal range.

[0051] In one embodiment, the formulation may further include one or more strains selected from the group consisting of strains of the genera Collinsella, Romboutsia, and Anaerostipes.

[0052] In this invention, the term "Collinsella" refers to a microorganism or a community thereof composed of species taxonomically belonging to the genus Collinsella. In this invention, Collinsella includes not only previously known strains but also strains having sequence homology of at least 70%, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95% when comparing 16S rRNA sequences with previously known Collinsella.

[0053] In one embodiment, the genus strain of Collinsella may be Collinsella aerofaciens.

[0054] In this invention, the term "Romboutsia" refers to a microorganism or a community thereof composed of species taxonomically belonging to the genus Romboutsia. In this invention, Romboutsia includes not only previously known strains but also strains having sequence homology of at least 70%, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95% when comparing 16S rRNA sequences with previously known Romboutsia.

[0055] In this invention, the term "Anaerostipes" refers to a microorganism or a community thereof composed of species taxonomically belonging to the genus Anaerostipes. In this invention, Anaerostipes includes not only previously known strains but also strains having sequence homology of at least 70%, more preferably at least 80%, even more preferably at least 90%, and most preferably at least 95% when comparing 16S rRNA sequences with previously known Anaerostipes.

[0056] In this document, the term "detectable preparation" refers to a substance that can be used to detect the presence of Blautia, Streptococcus, Eubacterium, Dorea, Clostridium UGG-014, and / or Weissella, which are diagnostic markers for mild cognitive impairment, in human feces. For example, it may be a primer, probe, antisense oligonucleotide, aptamer, or antibody capable of specifically detecting organic biomolecules such as proteins, nucleic acids, lipids, glycolipids, glycoproteins, or sugars (monosaccharides, disaccharides, oligosaccharides, etc.) that are specifically present in the said strains.

[0057] In this document, the term "primer" refers to a sequence of 7 to 50 nucleic acids capable of forming base pairs complementary to the template strand and functioning as a starting point for template strand replication. Primers are usually synthesized, but may also be used from naturally occurring nucleic acids. The sequence of the primer does not necessarily have to be exactly the same as the sequence of the template, but is sufficiently complementary to hybridize with the template. Additional features that do not alter the basic properties of the primer may be incorporated. Examples of additional features that may be incorporated include, but are not limited to, methylation, capping, substitution of one or more nucleic acids with homologues, and modification between nucleic acids. Preferably, the primer of the present invention may be a primer capable of amplifying the 16S rRNA of Blautia, Streptococcus, Eubacterium, Dorea, Clostridium UGG-014, and / or Weissella.

[0058] In this institution, the term "16S rRNA" refers to rRNA that constitutes the 30S subunit of prokaryotic ribosomes. Since it contains a conserved region common to all species and a hypervariable region capable of classifying specific species, microorganisms can be identified through sequencing analysis. In particular, while there is little diversity among the same species, diversity appears among different species, so prokaryotes can be usefully identified by comparing the sequences of 16S rRNA. Additionally, since 16S rDNA is the gene that codes for 16S rRNA, microorganisms can also be identified using 16S rDNA.

[0059] The above primers can be used to amplify 16S rRNA (or 16S rDNA) sequences specific to Blautia, Streptococcus, Eubacterium, Dorea, Clostridium UGG-014, and / or the genera Weissella, and the presence of Blautia, Streptococcus, Eubacterium, Dorea, Clostridium UGG-014, and / or the genera Weissella can be detected through the production of a desired product as a result of sequence amplification. Various methods known in the art may be used for sequence amplification using primers. For example, polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR), multiplex PCR, touchdown PCR, hot start PCR, nested PCR, booster PCR, real-time PCR, differential display PCR (DD-PCR), rapid amplification of cDNA ends (RACE), inverse polymerase chain reaction, vectorette PCR, TAIL-PCR (thermal asymmetric interlaced PCR), ligase chain reaction, repair chain reaction, transcription-mediated amplification, self-maintaining sequence replication, or selective amplification reaction of a target sequence may be used, but the scope of the present invention is not limited thereto.

[0060] In addition, the strain detection agent in the present invention may be an antibody, and the corresponding strain may be detected using an immunological method based on an antigen-antibody reaction. Analytical methods for this purpose include, but are not limited to, Western blot, ELISA (enzyme-linked immunosorbent assay), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, FACS (fluorescence activated cell sorter), or protein chip. Furthermore, molecular and immunological methods widely used in the art may be used to detect the microorganism of the present invention.

[0061]

[0062] A diagnostic kit for mild cognitive impairment comprising a diagnostic composition in another aspect may be provided. In the diagnostic kit, the terms and elements mentioned that are identical to those already mentioned are as described above.

[0063] The above kit may include detection agents such as primers, probes, antisense oligonucleotides, aptamers, or antibodies for detecting the microorganisms, as well as one or more other component compositions, solutions, or devices suitable for the analysis method.

[0064] In one embodiment, a kit containing primers specific to the strain genus and / or species may be a kit containing essential elements for performing an amplification reaction such as PCR. For example, the PCR kit may include a test tube or other suitable container, reaction buffer, deoxynucleotides (dNTPs), enzymes such as Taq-polymerase and reverse transcriptase, DNase, RNAse inhibitor, DEPC-water, or sterile water.

[0065] In another aspect, a method for providing information necessary for diagnosing mild cognitive impairment may be provided, comprising the step of detecting strains of the genus Blaufia, Streptococcus, Bacteroides, Eubacterium hallii, Dorea, Clostridia UGG-014, and Weisella from a fecal sample of a subject. In the method, the terms mentioned that are identical to those already mentioned are as described above.

[0066] In one embodiment, when a strain of the genus Blautia is included in the total sample at a concentration of 0.01 to 0.1 weight%, a step of determining mild cognitive impairment may be included. For example, if Blautia genus strains are included in the total sample in an amount of 0.01 to 0.1 wt%, 0.01 to 0.08 wt%, 0.01 to 0.06 wt%, 0.01 to 0.04 wt%, 0.01 to 0.02 wt%, 0.02 to 0.1 wt%, 0.02 to 0.08 wt%, 0.02 to 0.06 wt%, 0.02 to 0.04 wt%, 0.04 to 0.1 wt%, 0.04 to 0.08 wt%, 0.04 to 0.06 wt%, 0.06 to 0.1 wt%, 0.06 to 0.08 wt%, or 0.08 to 0.1 wt%, the method may include a step of determining mild cognitive impairment. If it falls outside the above range, it may not be possible to accurately monitor the weight of intestinal strains and diagnose mild cognitive impairment by comparing it to dementia.

[0067] In one embodiment, the method may include a step of determining mild cognitive impairment when the Streptococcus genus strain is included in the total sample at 0.05 to 0.1 weight%. For example, the method may include a step of determining mild cognitive impairment when the Streptococcus genus strain is included in the total sample at 0.05 to 0.1 weight%, 0.05 to 0.09 weight%, 0.05 to 0.08 weight%, 0.05 to 0.07 weight%, 0.05 to 0.06 weight%, 0.06 to 0.1 weight%, 0.06 to 0.09 weight%, 0.06 to 0.08 weight%, 0.06 to 0.07 weight%, 0.07 to 0.1 weight%, 0.07 to 0.09 weight%, or 0.07 to 0.08 weight%. If it falls outside the above range, it may not be possible to accurately monitor the weight of intestinal strains and diagnose mild cognitive impairment by comparing it to dementia.

[0068] In one embodiment, when a strain of the genus Clostridia UGG-014 is included in the total sample at a concentration of 0.01 to 0.1 weight%, a step of determining mild cognitive impairment may be included. For example, if a strain of the genus Clostridia UGG-014 is included in the total sample in an amount of 0.01 to 0.1 wt%, 0.01 to 0.08 wt%, 0.01 to 0.06 wt%, 0.01 to 0.04 wt%, 0.01 to 0.02 wt%, 0.02 to 0.1 wt%, 0.02 to 0.08 wt%, 0.02 to 0.06 wt%, 0.02 to 0.04 wt%, 0.04 to 0.1 wt%, 0.04 to 0.08 wt%, 0.04 to 0.06 wt%, 0.06 to 0.1 wt%, 0.06 to 0.08 wt%, or 0.08 to 0.1 wt%, the method may include a step of determining mild cognitive impairment. If it falls outside the above range, it may not be possible to accurately monitor the weight of intestinal strains and diagnose mild cognitive impairment by comparing it to dementia.

[0069] In one embodiment, if a strain of the genus Weissella is included in the total sample at a concentration of 0.01 to 0.1 weight%, the method may include a step of determining mild cognitive impairment. For example, if a strain of the genus Weissella is included in the total sample in an amount of 0.01 to 0.1 wt%, 0.01 to 0.08 wt%, 0.01 to 0.06 wt%, 0.01 to 0.04 wt%, 0.01 to 0.02 wt%, 0.02 to 0.1 wt%, 0.02 to 0.08 wt%, 0.02 to 0.06 wt%, 0.02 to 0.04 wt%, 0.04 to 0.1 wt%, 0.04 to 0.08 wt%, 0.04 to 0.06 wt%, 0.06 to 0.1 wt%, 0.06 to 0.08 wt%, or 0.08 to 0.1 wt%, the method may include a step of determining mild cognitive impairment. If it falls outside the above range, it may not be possible to accurately monitor the weight of intestinal strains and diagnose mild cognitive impairment by comparing it to dementia.

[0070] In one embodiment, the gut microbial communities of patients with mild cognitive impairment and patients with dementia were found to be statistically significant within the above range in the total sample. Therefore, mild cognitive impairment can be diagnosed by determining the weight range of the strains from the subject's fecal sample.

[0071] Preferred embodiments are presented below to aid in understanding the present invention. However, the following embodiments are provided merely to facilitate a better understanding of the invention, and the scope of the invention is not limited by the following embodiments.

[0072]

[0073] [Experimental Method]

[0074] 1. Subject

[0075] All subjects were Korean and were recruited from two locations: the Memory Clinic under Ajou University Hospital and the Suwon City Senior Mental Health Center. Individuals with a current or past history of serious neurological or medical conditions (e.g., Parkinson's disease, cerebral infarction, organ failure) that could interfere with the study were excluded. Stool samples were collected from 292 subjects for the experiment.

[0076] The general characteristics of the subjects are as shown in Table 1 below.

[0077] VariableCategoryMean(SD) / N(%)SexFemale190 (70.9)Male78 (29.1)Age72.5 (6.9)Education(Years)7.6 (4.8)BMI23.8 (3.4)MADRS15.2 (11.5)Antidepressant UseNo136 (50.7)Yes132 (49.3)MMSE23.4 (4.7)KBAI9.1 (10.1)MNA20.6 (4.8)IPAQ1126.7 (1790.2)Lifetime Drinking(g)10980.6 (34928.8)Lifetime Smoking(pack-year)7.7 (17.9)Psychiatric DxNone62 (23.1)Major Dep124 (46.2)Minor Dep82 (30.4)Cognitive DxSCD17 (6.3)MCI189 (70.5)AD40 (14.9)OtherDementia22 (8.2)HypertensionNo133 (49.6)Yes135 (50.4)Myocardial infractionNo260 (97.0)Yes8 (3.0)Cardiac IschemiaNo245 (91.4)Yes23 (8.6)Diabetes MellitusNo212 (79.1)Yes56 (20.9)Site1146 (54.5)2122 (45.5)

[0078]

[0079] 2. Psychiatric and Neuropsychological Evaluation Methods

[0080] A comprehensive psychiatric and neuropsychological evaluation was performed on all subjects.

[0081] The diagnosis of major or mild depressive disorder was determined by a psychiatrist. Dementia was assessed using the Clinical Dementia Rating (CDR), and mild cognitive impairment (MCI) was diagnosed based on a CDR score of 0.5 and the Extended Mayo Criteria for mild cognitive impairment. General cognitive function was assessed using the Mini-Mental State Examination (MMSE).

[0082] The evaluated subjects were divided into a group with only subjective memory impairment (hereinafter, SMI group), a group with only mild cognitive impairment (hereinafter, MCI group), a group with both subjective memory impairment and mild cognitive impairment (hereinafter, SMI+MCI group), and a dementia group (hereinafter, Dementia group).

[0083]

[0084] [Example]

[0085] Example 1. Sample Preparation and DNA Extraction

[0086] Stool samples were collected from the Ajou University Hospital Biobank using sterile stool containers and stored at -20°C until further processing. The V3 and V4 regions of the 16 S rRNA marker gene were amplified using the Illumina MiSeq platform.

[0087] Pair end reads of 300 bases in length were generated in each direction using V3 and V4 Illumina adapters and double barcode sequences. Then, the demultiplexed sequences were preprocessed and primers were trimmed.

[0088]

[0089] Example 2. Analysis of microbial composition and community diversity

[0090] The sequence information obtained in Example 1 was processed using MiSeq (Illumina) according to the barcode algorithm and primer sequences. After all microbial community samples were sequenced, taxonomic analysis was performed using a profiling program with SILVA DB.

[0091]

[0092] [Experimental Results]

[0093] 1. Confirmation of microbial community diversity

[0094] Beta diversity was assessed to determine microbial community diversity between the SMI+MCI group and the Dementia group. Specifically, the Bray-Curtis distance method was used to determine beta diversity, and additionally, Principal coordinates analysis (PCoA) was performed to confirm the beta diversity of genuses and species in the samples.

[0095] Figure 1 is a figure confirming the beta diversity of microbial genera between the SMI+MCI group and the Dementia group according to one embodiment.

[0096] Figure 2 is a figure confirming the beta diversity by microbial species between the SMI+MCI group and the Dementia group according to one embodiment.

[0097] As a result, as shown in Figures 1 and 2, sufficient beta diversity of genera and species of intestinal microorganisms was confirmed between the SMI+MCI group and the Dementia group.

[0098]

[0099] 2. Comparison of Microbial Community Composition Between Patients with Mild Cognitive Impairment and Dementia

[0100] The microbial composition characteristics between the SMI+MCI group and the Dementia group were confirmed, and the classification of microbial genera is shown in Table 2.

[0101] SMI+MCIDementiat.testTaxonMEANSDMEANSDp-valued__Bacteria;p__Firmicutes;c__Clostridia;o__Lachnospirales;f__Lachnospiracea e;g__Blautia0.0941870.0861360.1261240.0881040.0076d__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacilli;f__Streptococc aceae;g__Streptococcus0.0629290.0893230.0384010.067640.0160d__Bacteria;p__Bacteroidota;c__Bacteroidea;o__Bacteroidales;f __Bacteroidaceae;g__Bacteroides0.0488630.0858260.0225680.0450210.0010d__Bacteria;p__Firmicutes;c__Clostridia;o__Lachnosp irales;f__Lachnospiraceae;g__[Eubacterium]_hallii_group0.0231780.0283190.0312210.0279290.0385d__Bacteria;p__Firmicutes;c __Clostridia;o__Lachnospirals;f__Lachnospiraceae;g__Dorea0.0109910.0113190.0145460.0130460.0281d__Bacteria;p__Firmicute s;c__Clostridia;o__Clostridia_UCG-014;f__Clostridia_UCG-014;g__Clostridia_UCG-0140.0167060.049050.0074020.0181710.0190d_ _Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Leuconostocaceae;g__Weissella0.0135890.0393260.0039030.0070630.0006d__Bacteria;p__Bacteroidota;c__Bacteroidia;o__Bacteroidales;f__Rikenellaceae;g__Alistipes0.0084560.0175940.0040030.0098560.0082d __Bacteria;p__Bacteroidota;c__Bacteroidia;o__Bacteroidales;f__Tannerellaceae;g__Parabacteroides0.0081880.0278360.0028320.007110.0095.

[0102]

[0103] In addition, the composition ratio and weight% of the microbial genera between the SMI+MCI group and the Dementia group are shown in Figures 3 and 4, respectively.

[0104] As a result, as shown in Table 2, Figures 3 and 4, the weight percentages of Blautia, Streptococcus, Bacteroides, Eubacterium hallii, Dorea, Clostridia UGG-014, and Weisella strains in the SMI+MCI group and the Dementia group were found to be statistically significant.

[0105] In addition, the composition ratio and weight% of microbial species between the SMI+MCI group and the Dementia group are shown in Figures 5 and 6, respectively.

[0106] As a result, as shown in Figures 5 and 6, it was confirmed that the weight percentage of Streptococcus salvarius and Weisella confusa strains in the SMI+MCI group and the Dementia group was statistically significant.

[0107]

[0108] Furthermore, the composition ratios of microbial genera among the SMI group, MCI group, and Dementia group are shown in Figures 7 and 8.

[0109] As a result, as shown in Figures 7 and 8, the weight percentage of strains of the genera Collinsella, Romboutsia, and Anaerostipes in the MCI group and the Dementia group was found to be statistically significant.

[0110] In addition, the composition ratio of microbial species among the SMI group, MCI group, and Dementia group is shown in Figures 9 and 10.

[0111] As a result, as shown in Figures 9 and 10, it was confirmed that the weight percentage of the Collinsella aerofaciens strain in the MCI group and the Dementia group was statistically significant.

[0112] Synthesizing the above results, the SMI+MCI group and the Dementia group show weight differences in intestinal microorganisms, specifically in Blautia genus strains, Streptococcus genus strains, Bacteroides genus strains, Eubacterium hallii genus strains, Dorea genus strains, Clostridia UGG-014 genus strains, and Weisella genus strains; specifically, there are weight differences in Streptococcus salvarius and Weisella confusa strains.

[0113] In addition, the MCI group and the Dementia group have weight differences in strains of the genera Collinsella, Romboutsia, and Anaerostipes, specifically, in the Collinsella aerofaciens strain.

[0114] Therefore, mild cognitive impairment can be diagnosed by monitoring the weight ratio or weight of the above strains in the intestines and comparing them to dementia.

[0115] The above descriptions are specific embodiments for carrying out the present disclosure. The present disclosure will include not only the embodiments described above, but also embodiments that can be simply modified or easily modified. Furthermore, the present disclosure will include technologies that can be easily modified and implemented using the embodiments described above. Accordingly, the scope of the present disclosure should not be limited to the embodiments described above, but should be defined by the claims set forth below as well as equivalents to the claims of the present disclosure.

Claims

1. A composition for diagnosing mild cognitive impairment comprising a preparation capable of detecting Blautia genus strains, Streptococcus genus strains, Bacteroides genus strains, Eubacterium hallii genus strains, Dorea genus strains, Clostridia UGG-014 genus strains, and Weisella genus strains from a fecal sample of a subject.

2. In claim 1, the Streptococcus genus strain is Streptococcus salvarius, and A composition for diagnosing mild cognitive impairment, wherein the above-mentioned Weisella genus strain is Weisella confusa.

3. A composition for diagnosing mild cognitive impairment according to claim 1, further comprising a preparation capable of detecting one or more strains selected from the group consisting of strains of the genera Collinsella, Romboutsia, and Anaerostipes.

4. A composition for diagnosing mild cognitive impairment, wherein, in claim 3, the genus strain of the cholinestera is *Colinsella aerofaciens*.

5. A composition for diagnosing mild cognitive impairment according to claim 1, wherein the preparation capable of detecting the strain is a primer, probe, antisense oligonucleotide, aptamer, or antibody specific to microorganisms.

6. A composition for diagnosing mild cognitive impairment, wherein, in claim 5, the primer is a primer capable of amplifying the 16S rRNA of the strain.

7. A kit for diagnosing mild cognitive impairment comprising the diagnostic composition of claims 1 to 6.

8. A method for providing information necessary for diagnosing mild cognitive impairment, comprising the step of detecting Blaufia strains, Streptococcus strains, Bacteroides strains, Eubacterium hallii strains, Dorea strains, Clostridia UGG-014 strains, and Weisella strains from a fecal sample of a subject.

9. In Paragraph 8, A method comprising the step of determining the subject as having mild cognitive impairment when the above-mentioned Blautia genus strain is included in the total sample at a concentration of 0.01 to 0.1 weight%, A method for providing information necessary for the diagnosis of mild cognitive impairment.

10. In Paragraph 8, A method comprising the step of determining the subject as having mild cognitive impairment when the above-mentioned Streptococcus strain is included in the total sample at 0.05 to 0.1 weight%, A method for providing information necessary for the diagnosis of mild cognitive impairment.

11. In Paragraph 8, A method comprising the step of determining the subject to have mild cognitive impairment when the above-mentioned Clostridia UGG-014 strain is included in the total sample at a concentration of 0.01 to 0.1 weight%, A method for providing information necessary for the diagnosis of mild cognitive impairment.

12. In Paragraph 8, A method comprising the step of determining the subject as having mild cognitive impairment when the above-mentioned Weisella genus strain is included in the total sample at a concentration of 0.01 to 0.1 weight%, A method for providing information necessary for the diagnosis of mild cognitive impairment.